Mechanistically, IAP0971 can deregulate the immunosuppression of the PD-1/PD-L1 axis while increasing the targeting of IL-15 to the tumor microenvironment and avoiding systemic non-specific activation; furthermore, IAP0971 has an IgG4-based structure, resulting in a weak effect such as ADCC and ADCP, and a long half-life (123). The gene discussed is PDCD1; the disease is neoplasm.